Inhibitory Concentration 50

"Inhibitory Concentration 50" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.

Descriptor ID	D020128
MeSH Number(s)	E05.940.350 G07.690.936.563
Concept/Terms	Inhibitory Concentration 50 Inhibitory Concentration 50 Concentration 50, Inhibitory IC50

Below are MeSH descriptors whose meaning is more general than "Inhibitory Concentration 50".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Toxicity Tests [E05.940]
Inhibitory Concentration 50 [E05.940.350]
Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Toxicological Phenomena [G07.690.936]
Inhibitory Concentration 50 [G07.690.936.563]

Below are MeSH descriptors whose meaning is related to "Inhibitory Concentration 50".

Below are MeSH descriptors whose meaning is more specific than "Inhibitory Concentration 50".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Inhibitory Concentration 50" by people in this website by year, and whether "Inhibitory Concentration 50" was a major or minor topic of these publications.

Bar chart showing 76 publications over 23 distinct years, with a maximum of 9 publications in 2002 and 2003

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
2001	2	2
2002	9	9
2003	9	9
2004	4	4
2005	4	4
2006	4	4
2007	1	1
2008	2	2
2009	1	1
2010	7	7
2011	7	7
2012	3	3
2013	5	5
2014	1	1
2015	3	3
2016	3	3
2017	1	1
2018	1	1
2019	1	1
2020	1	1
2021	2	2
2024	3	3
2025	2	2

Below are the most recent publications written about "Inhibitory Concentration 50" by people in Profiles.

Okitwi M, Orena S, Tumwebaze PK, Katairo T, Taremwa Y, Byaruhanga O, Tukwasibwe S, Nsobya SL, Legac J, Bailey JA, Cooper RA, Conrad MD, Rosenthal PJ. Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019-2024. Nat Commun. 2025 Aug 09; 16(1):7353.

View in: PubMed
Rosado J, Fola AA, Cojean S, Sarrasin V, Copp?e R, Bailly J, Zaffaroulah R, Bouzayene A, Cic?ron L, Houz? L, Crudale R, Musset L, Thellier M, Pradines B, Clain J, Bailey JA, Houz? S. Assessment of ex vivo antimalarial drug efficacy in African Plasmodium falciparum parasite isolates, 2016-2023: a genotype-phenotype association study. EBioMedicine. 2025 Aug; 118:105835.

View in: PubMed
Okitwi M, Shoue DA, Checkley LA, Orena S, Ceja FG, Taremwa Y, Tumwebaze PK, Katairo T, Byaruhanga O, Sievert MA, Garg S, Kreutzfeld OK, Legac J, Bailey JA, Nsobya SL, Conrad MD, Rosenthal PJ, Ferdig MT, Cooper RA. The extended recovery ring-stage survival assay is a scalable alternative for artemisinin susceptibility phenotyping of fresh Plasmodium falciparum isolates. Antimicrob Agents Chemother. 2024 12 05; 68(12):e0118324.

View in: PubMed
Kreutzfeld O, Orena S, Okitwi M, Tumwebaze PK, Byaruhanga O, Katairo T, Conrad MD, Legac J, Garg S, Crudale R, Aydemir O, Giesbrecht D, Nsobya SL, Blasco B, Duffey M, Rouillier M, Bailey JA, Cooper RA, Rosenthal PJ. Ex vivo susceptibilities to ganaplacide and diversity in potential resistance mediators in Ugandan Plasmodium falciparum isolates. Antimicrob Agents Chemother. 2024 09 04; 68(9):e0046624.

View in: PubMed
Noto Guillen M, Li C, Rosener B, Mitchell A. Antibacterial activity of nonantibiotics is orthogonal to standard antibiotics. Science. 2024 04 05; 384(6691):93-100.

View in: PubMed
Mart?n Monreal MT, Rebak AS, Massarenti L, Mondal S, ?enolt L, ?dum N, Nielsen ML, Thompson PR, Nielsen CH, Damgaard D. Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4. Front Immunol. 2021; 12:716250.

View in: PubMed
Lockbaum GJ, Reyes AC, Lee JM, Tilvawala R, Nalivaika EA, Ali A, Kurt Yilmaz N, Thompson PR, Schiffer CA. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. Viruses. 2021 01 25; 13(2).

View in: PubMed
Pontes KAO, Silva LS, Santos EC, Pinheiro AS, Teixeira DE, Peruchetti DB, Silva-Aguiar RP, Wendt CHC, Miranda KR, Coelho-de-Souza AN, Leal-Cardoso JH, Caruso-Neves C, Pinheiro AAS. Eugenol disrupts Plasmodium falciparum intracellular development during the erythrocytic cycle and protects against cerebral malaria. Biochim Biophys Acta Gen Subj. 2021 03; 1865(3):129813.

View in: PubMed
Lock M, Korn M, Wilson J, Sena-Esteves M, Gao G. Measuring the Infectious Titer of Recombinant Adenovirus Using Tissue Culture Infection Dose 50% (TCID50) End-Point Dilution and Quantitative Polymerase Chain Reaction (qPCR). Cold Spring Harb Protoc. 2019 08 01; 2019(8).

View in: PubMed
Zhang M, Park EJ, Kondratyuk TP, Pezzuto JM, Sun D. Synthesis and Structure-Activity Relationships of Tetrahydro-?-carboline Derivatives as Anticancer and Cancer-chemopreventive Agents. Anticancer Res. 2018 Aug; 38(8):4425-4433.

View in: PubMed

People

Explore

Similar Concepts

Top Journals